SIEGFRIED GROUP

1. An improved product range for customers is to be achieved, especially, by means of worldwide expansion into solid finished drug dosage forms (tablets, capsules). Today, Siegfried's production in this area is based in Hal Far (Malta) and since the acquisition of the drug product manufacturing facility from Arena Pharmaceuticals GmbH in the spring 2018 as well in Zofingen (Switzerland).,The corresponding pharmaceutical development is located in Zofingen. By means of an acquisition, either in North America or in Europe, Siegfried aims to gain access to additional competitive capacity and formulation technologies. Siegfried plans to expand production capacity hand in hand with further strengthening development competencies... 2. Growth initiatives within the value chain of the existing business will make a significant contribution toward targeted growth and the expansion of critical size of sales. Siegfried focuses on the recently commenced plant expansion in Hameln, which serves the..

Also known as: Siegfried (Nantong) Pharmaceuticals Co. Ltd., Siegfried AG, Siegfried Evionnaz SA, Siegfried Hameln GmbH, Siegfried Holding, Siegfried Holding AG, Siegfried Ltd., Siegfried Malta Ltd, Siegfried USA, LLC, The Siegfried Group

Primary location: Zofingen Switzerland